Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.

ABSTRACT:

Background and objective

Denosumab is a valuable and safe therapy for skeletal disorders in adults and has received regulatory approval to treat osteoporosis and bone metastases. However, denosumab is not licensed for pediatric use due to a lack of high-quality prospective research on children. This study aimed to describe and discuss the benefits and disadvantages of denosumab in treating bone diseases in children and to summarize the current understanding of the role of denosumab therapy in children.

Methods

A narrative review was conducted using the literature retrieved from the PubMed, Embase, and Cochrane Library databases.

Key content and findings

In children with type 6 osteogenesis imperfecta (OI), juvenile Paget disease (JPD), and secondary osteoporosis who s

SUBMITTER: Wang D 

PROVIDER: S-EPMC10080477 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature